These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 18538948)
81. STING Agonists as Cancer Therapeutics. Amouzegar A; Chelvanambi M; Filderman JN; Storkus WJ; Luke JJ Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070756 [TBL] [Abstract][Full Text] [Related]
82. Magnetic Resonance Imaging for Translational Research in Oncology. Fiordelisi MF; Cavaliere C; Auletta L; Basso L; Salvatore M J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31698697 [TBL] [Abstract][Full Text] [Related]
83. Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes. Guo H; Kang H; Tong H; Du X; Liu H; Tan Y; Yang Y; Wang S; Zhang W Eur Radiol; 2019 Apr; 29(4):1893-1902. PubMed ID: 30276676 [TBL] [Abstract][Full Text] [Related]
84. Assessment of the direct effects of DDAH I on tumour angiogenesis in vivo. Papaevangelou E; Boult JKR; Whitley GS; Robinson SP; Howe FA Angiogenesis; 2018 Nov; 21(4):737-749. PubMed ID: 29721731 [TBL] [Abstract][Full Text] [Related]
85. Use of Ultrasmall Superparamagnetic Iron Oxide Enhanced Susceptibility Weighted Imaging and Mean Vessel Density Imaging to Monitor Antiangiogenic Effects of Sorafenib on Experimental Hepatocellular Carcinoma. Yang S; Lin J; Lu F; Han Z; Fu C; Gu H Contrast Media Mol Imaging; 2017; 2017():9265098. PubMed ID: 29097941 [TBL] [Abstract][Full Text] [Related]
86. Improving tumour heterogeneity MRI assessment with histograms. Just N Br J Cancer; 2014 Dec; 111(12):2205-13. PubMed ID: 25268373 [TBL] [Abstract][Full Text] [Related]
91. Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours. Thompson G; Mills SJ; Coope DJ; O'Connor JP; Jackson A Br J Radiol; 2011 Dec; 84 Spec No 2(Spec Iss 2):S127-44. PubMed ID: 22433824 [TBL] [Abstract][Full Text] [Related]
92. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. Mason RP; Zhao D; Liu L; Trawick ML; Pinney KG Integr Biol (Camb); 2011 Apr; 3(4):375-87. PubMed ID: 21321746 [TBL] [Abstract][Full Text] [Related]
93. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. McPhail LD; McIntyre DJ; Ludwig C; Kestell P; Griffiths JR; Kelland LR; Robinson SP Neoplasia; 2006 Mar; 8(3):199-206. PubMed ID: 16611413 [TBL] [Abstract][Full Text] [Related]
94. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging. McPhail LD; Griffiths JR; Robinson SP Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313 [TBL] [Abstract][Full Text] [Related]
95. [Iron-oxide-enhanced MR imaging of inflammatory atherosclerotic lesions: overview of experimental and initial clinical results]. Schmitz SA Rofo; 2003 Apr; 175(4):469-76. PubMed ID: 12677500 [TBL] [Abstract][Full Text] [Related]
96. Antivascular therapy of cancer: DMXAA. Baguley BC Lancet Oncol; 2003 Mar; 4(3):141-8. PubMed ID: 12623359 [TBL] [Abstract][Full Text] [Related]
97. Vessel size index magnetic resonance imaging to monitor the effect of antivascular treatment in a rodent tumor model. Howe FA; McPhail LD; Griffiths JR; McIntyre DJ; Robinson SP Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1470-6. PubMed ID: 18538948 [TBL] [Abstract][Full Text] [Related]
98. Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126. Robinson SP; Howe FA; Griffiths JR; Ryan AJ; Waterton JC Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):872-9. PubMed ID: 17889267 [TBL] [Abstract][Full Text] [Related]